Диссертация (1139774), страница 28
Текст из файла (страница 28)
Trends in treatment of newly treated schizophreniaspectrum disorder patients in Taiwan from 1999 to 2006 // Pharmacoepidemiology andDrug Safety. - 2012. - V. 21. - P. 989-96.273. Young S.L., Taylor M., Lawrie S.M. First do no harm. A systematic review of theprevalence and management of antipsychotic adverse effects // Journal ofPsychopharmacology. - 2015.
- V. 29(4). - P. 353-62.274. Yu Z., Jiang H., Shao L., Zhou Y., Shi H., Ruan B. Use of antipsychotics and riskof myocardial infarction: a systematic review and meta-analysis // British Journal ofClinical Pharmacology. - 2016. - V. 82. - P. 624-32.275.
Zhang J.P., Malhotra A.K. Pharmacogenetics and antipsychotics: therapeuticefficacy and side effects prediction // Expert Opinion on Drug Metabolism &Toxicology. - 2011. - V. 7(1). - P. 9-37.276. Zhang Z., Hou G., Zhang X., Yao H., Sha W., Zhang X. Pharmacogeneticassessmentofantipsychotic-inducedtardivedyskinesia:contributionof5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variantallele (Gly) and MnSOD wild allele (Val) [in Chinese] // Zhonghua Yi Xue Yi ChuanXue Za Zhi. - 2003. - V. 20(2). - P. 98-102.163277. Zhou S.F. Polymorphism of human cytochrome P450 2D6 and its clinicalsignificance: part II. // Clinical Pharmacokinectics. - 2009. - V. 48(12). - P.
761-804..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
